Achievement of successful drug withdrawal at week 104
low disease
REMISSION, DISEASE, DISEASE
The changes in CDAI recorded over 104 weeks are shown in Sankey diagram describing proportion of patients per CDAI disease activity category over time. (A) Tofacitinib discontinuation arm (n=56), (B) methotrexate discontinuation arm (n=57). Data are n (%). CDAI, Clinical Disease Activity Index.After the withdrawal of each drug, the proportion of patients with disease relapses increased with time in both the tofacitinib and MTX discontinuation groups. Out of patients who discontinued tofacitinib, 29.2% (7/24) of patients remained in remission (one patient experienced a period of low disease activity, but subsequently achieved remission again), and 41.7% (10/24) maintained low disease activity at week 104 in patients who achieved remission at week 52 (When considering the percentages of patients who achieved both clinical remission and successful discontinuation from baseline, the tofacitinib discontinuation group had 12.5% (7/56) of patients achieving this endpoint, whereas the MTX discontinuation group had 17.5% (10/57) of patients achieving this endpoint, and there were no statistical differences (p=0.4533 for remission and p=0.5135 for low disease activity) (